Sutro Biopharma (STRO) Research & Development (2017 - 2026)

Sutro Biopharma has reported Research & Development for 9 years, with the latest figure at $36.6 million in Q4 2025.

• Quarterly Research & Development fell 48.42% year-over-year to $36.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $166.4 million (down 33.97% YoY) and the FY2025 annual result came in at $166.4 million, down 33.97% from the prior year.
• Research & Development slipped to $36.6 million in Q4 2025 per STRO's latest filing, from $39.9 million in the prior quarter.
• Over five years, Research & Development peaked at $71.0 million in Q4 2024 and troughed at $22.6 million in Q1 2021.
• A 5-year average of $42.0 million and a median of $39.6 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development surged 49.12% in 2024, then tumbled 48.42% in 2025.
• Over 5 years, Research & Development stood at $29.9 million in 2021, then surged by 44.13% to $43.1 million in 2022, then rose by 24.64% to $53.8 million in 2023, then soared by 32.12% to $71.0 million in 2024, then sank by 48.42% to $36.6 million in 2025.
• According to Business Quant data, Research & Development over the past three periods registered $36.6 million, $39.9 million, and $38.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.